Dr. Reddy's Laboratories Launches Tadalafil Tablets USP in the US Market
29 March 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. ((BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis (tadalafil) Tablets in the United States market, approved by the US Food and Drug Administration (USFDA), the company said.

The Cialis brand and generic had US sales of approximately USD 1.7bn MAT for the most recent twelve months ending in January 2019 according to IMS Health.

Dr. Reddy's Tadalafil Tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.

Cialis is a trademark of Eli Lilly and Company.

Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Its major markets include USA, India, Russia and CIS countries, and Europe.